Predictive iPSC-Based Safety Profiling for ADCs Using a Multi-Tissue Human Platform

This poster presents Ncardia’s fully human, iPSC-derived multi-tissue platform designed to assess safety and de-risk antibody–drug conjugates (ADCs) through mechanistically relevant, functional toxicity profiling across key organ systems.

Download it now for a closer look at:

• How a seven-tissue iPSC-derived panel enables assessment of on-target and off-tumor toxicity across physiologically relevant human cell types
  
• A case study on Cetuximab-MMAE demonstrating how the platform recapitulates clinically observed toxicity patterns, particularly skin-related adverse effects
• How real-time impedance-based assays provide dynamic, quantitative insights into cytotoxicity and tissue-specific susceptibility over time
• The ability to distinguish between supratherapeutic toxicity and clinically relevant exposure, supporting more informed decision-making during development

• How integrating in silico target expression data with functional in vitro assays strengthens mechanistic understanding of safety risks